This is the official website of the 2nd phase of the Public Health Genomics European Network (PHGEN) project, more specifically known as PHGEN II. All information regarding the work, activities and research of PHGEN II can be found on this website. For further information, please do not hesitate to contact us.
Public Health Genomics
Modern research in genetics and molecular biology offers new opportunities for the promotion of population health. Public Health Genomics (PHG) is the responsible and effective integration of genome-based knowledge and technologies into public policy and into health services for the benefit of population health.
The Public Health Genomics European Network (PHGEN) is a cornerstone in the development of Publich Health Genomics in Europe. PHGEN is coordinated from the European Centre for Public Health Genomics (ECPHG) at Maastricht University in The Netherlands. It operates with several sister institutions in Europe including GENAR from Turkey as the first partner in the network. PHGEN is funded by the General Directorate for Health and Consumer Protection (DG SANCO) under the Health Programme. After successful evaluaton of PHGEN I, PHGEN now moves to the second funding period (PHGEN II) from June 2009 till May 2012.
PHGEN II produces the first edition of "European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies". The guidelines assist Member States, Applicant and EFTA-EEA countries with evidence-based guidance on timely and responsible integration of population health. Since genetic determinants are hardly recognized as playing a key role in understanding diseases and target-oriented prevention, ongoing exchange of knowledge and best practice in this rapid growing field is needed. The project uses an interdisciplinary approach and reviews the available evidence including evidence emerging from relevant European research and health action networks to avoid duplication of EU work and funding and to develop agreed on best practice guidelines. Key experts such as Public Health experts, EU lawyers, Human Geneticists, Ethicists, System Biologists, HTA experts and patient groups are involved in PHGEN II. Expertise from networks like EuroGentest, EUnetHTA, NUGO is provided by the project consortium to assess existing guidelines, identify gaps and set up a coherent, evidence-based framework fro quality assurance, provision and use of genome-based information and technologies.
PHGEN II is a follow-up of PHGEN I (DG SANCO 2006-2008). Whereas PHGEN I identified the need for European best practice guidelines ("mapping exercise"), PHGEN II systematically builds on the work of PHGEN I by developing these guidelines. It uses the concept of "genome-based information and technologies" (Bellagio-Model) which PHGEN I established as a scientific benchmark in Europe. While protecting human rights, equity in healthcare and solidarity amongst citizens, it meets the Lisbon Agenda objectives and values of the Health Strategy. In the long run, the best practice guidelines will highly contribute to the reduction of the burden of disease in Europe.
PHGEN II project is supported by a grant from the European Commission
Duration period: 1 June 2009 - 30 November 2012
EU-Project No. 20081302
PHGEN I ended in March 2009. PHGEN II continued at Maastricht University and was led by Prof. Dr. Angela Brand. PHGEN II has officially ended on 30 November 2012 with the reporting period ending on 30 January 2013.
Follow us on TWITTER!
PHGEN II as a Success Story, Biobanks and Personalized Medicine
PHGEN II has been selected as one of the success stories funded by the EU heath programs. The detailed report can be found here. PHGEN II has also been mentioned in the report of the European Commission expert group on biobanks and can be found here. Further our project has been pubished in the European Science Foundation's 'Personalised Medicine for the European Citizen' and can be found here.
Meeting of European Alliance for Personalised Medicine
Commissioner Dalli (speech) and Cyprus Minister Mavroyiannis launched in Brussels on 18 September 2012 the manifesto by the newly-formed European Alliance for Personalised Medicine (EAPM), which brings together patient groups, academia, health professionals and industry, as well as the European Commission and the European Medicines Agency. This news has been covered by APM Health and the European Parliament Magazine. Click here for the picture of our PHGEN coordinator discussing with Commissioner Dalli.
During the final meeting in April 2012 in Rome, the PHGEN II European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies have been officially endorsed as the "Declaration of Rome 2012" by the European Member States as well as European key Institutions and Organizations such as EMA. The "Declaration of Rome 2012" has been published in the Journal "Drug Metabolism and Drug Interactions". It can be downloaded for free at the journal website here. Also a related editorial has also been published in the same journal which can be found at the journal website here. The "Declaration of Rome 2012" is the summary of the European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies produced in the form of 3 individual reports (QA, Provision & Use) by the PHGEN II consortium. These 3 parts can be accees below:
PHGEN II Extension Granted
Given the success of the project and realizing the deliverables go beyond the current deliverables, the PHGEN II project has been granted a 6 months cost netural extension by the EAHC. Therefore, the project will continue till the 30 November 2012. Originally the project was till 30 May 2012.
PHGEN II Final Meeting Rome
The PHGEN II final meeting (endorsement panel) took place in Rome, Italy. It was a success. Further information can be found here.
PHGEN II has released the definitions list which will be used as the guiding tools for the development of the guidelines. These constitute definitions developed during PHGEN I as well as new definitions. This can be found by clicking the link here.
The 3rd and final Steering Committee Meeting of PHGEN II took place on 23 February 2012 in Maastricht, The Netherlands. Further information can be found here.
ITFoM is one of six pilot projects in the European Future and Emerging Technologies Flagship scheme. These projects are vying for €1 billion funding from both the European Commission, Member States and other sources over ten years in order to generate a scientific revolution. Further information can be found from here.
Old information and news of PHGEN II can be found in the Archives here.
Public Health Genomics Journal
(Journal published in collaboration with GRaPH-Int)
'Public Health Genomics' is the first peer-reviewed international journal to focus on the translation of genome-based knowledge and technologies into public policy, disease prevention and the improvement of population health. It is a multidisciplinary bi-monthly forum containing conceptual and original research articles, editorials, reviews, short communications, country reports, case studies, viewpoints, news and various other features about the nature of public health genomics and related concepts.
For more details please visit http://www.karger.com/phg
PHGEN II is currently also developing a Wiki. This can be accessed here.
PHGEN II is coordinated by the Institute for Public Health Genomics (IPHG) at Maastricht University. The publication list contributed by partners of PHGEN II can be found here.
The IPHG coordinated the bachelor's program Public Health Genomics. The output of the successful course was a report made by the students with supervision from their supervisors. The report can be found here.
PHGEN II events have now officially ended.